Targeting DYRK1B may therefore overcome the inefficient therapeutic response of pancreatic cancer patients to SMO-inhibitors that target canonical paracrine signaling in the tumor environment rather than non-canonical GLI activity in the epithelial tumor compartment [58-61]. The gene discussed is SMO; the disease is pancreatic neoplasm.